192 related articles for article (PubMed ID: 20930628)
1. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer.
Ino K
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):13-8. PubMed ID: 20930628
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.
Nonaka H; Saga Y; Fujiwara H; Akimoto H; Yamada A; Kagawa S; Takei Y; Machida S; Takikawa O; Suzuki M
Int J Oncol; 2011 Jan; 38(1):113-20. PubMed ID: 21109932
[TBL] [Abstract][Full Text] [Related]
4. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.
Inaba T; Ino K; Kajiyama H; Yamamoto E; Shibata K; Nawa A; Nagasaka T; Akimoto H; Takikawa O; Kikkawa F
Gynecol Oncol; 2009 Nov; 115(2):185-92. PubMed ID: 19665763
[TBL] [Abstract][Full Text] [Related]
5. Marrying immunotherapy with chemotherapy: why say IDO?
Muller AJ; Prendergast GC
Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
[TBL] [Abstract][Full Text] [Related]
7. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
8. Role of IDO in organ transplantation: promises and difficulties.
Löb S; Königsrainer A
Int Rev Immunol; 2009; 28(3-4):185-206. PubMed ID: 19811321
[TBL] [Abstract][Full Text] [Related]
9. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival.
Ino K; Yamamoto E; Shibata K; Kajiyama H; Yoshida N; Terauchi M; Nawa A; Nagasaka T; Takikawa O; Kikkawa F
Clin Cancer Res; 2008 Apr; 14(8):2310-7. PubMed ID: 18413819
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase in tumor induced tolerance.
Liu XQ; Wang X
Chin Med J (Engl); 2009 Dec; 122(24):3072-7. PubMed ID: 20137504
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model.
Yoshida N; Ino K; Ishida Y; Kajiyama H; Yamamoto E; Shibata K; Terauchi M; Nawa A; Akimoto H; Takikawa O; Isobe K; Kikkawa F
Clin Cancer Res; 2008 Nov; 14(22):7251-9. PubMed ID: 19010841
[TBL] [Abstract][Full Text] [Related]
12. IDO and outcomes in ovarian cancer.
Nelson BH
Gynecol Oncol; 2009 Nov; 115(2):179-80. PubMed ID: 19822256
[No Abstract] [Full Text] [Related]
13. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
[TBL] [Abstract][Full Text] [Related]
14. The immunoregulatory role of IDO-producing human dendritic cells revisited.
Terness P; Chuang JJ; Opelz G
Trends Immunol; 2006 Feb; 27(2):68-73. PubMed ID: 16406698
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
16. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Takao M; Okamoto A; Nikaido T; Urashima M; Takakura S; Saito M; Saito M; Okamoto S; Takikawa O; Sasaki H; Yasuda M; Ochiai K; Tanaka T
Oncol Rep; 2007 Jun; 17(6):1333-9. PubMed ID: 17487387
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.
Brandacher G; Perathoner A; Ladurner R; Schneeberger S; Obrist P; Winkler C; Werner ER; Werner-Felmayer G; Weiss HG; Göbel G; Margreiter R; Königsrainer A; Fuchs D; Amberger A
Clin Cancer Res; 2006 Feb; 12(4):1144-51. PubMed ID: 16489067
[TBL] [Abstract][Full Text] [Related]
18. Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels.
Jiang GM; He YW; Fang R; Zhang G; Zeng J; Yi YM; Zhang S; Bu XZ; Cai SH; Du J
Int J Biochem Cell Biol; 2010 Nov; 42(11):1840-6. PubMed ID: 20691806
[TBL] [Abstract][Full Text] [Related]
19. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.
Di Pucchio T; Danese S; De Cristofaro R; Rutella S
Expert Opin Ther Pat; 2010 Feb; 20(2):229-50. PubMed ID: 20100004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
